Emodin Enhances Rosiglitazone’s Therapeutic Profile by Dual Modulation of SREBP1-Mediated Adipogenesis and PPARγ-Driven Thermogenesis
Meng Li, Yi-Rong Wang, Xue Wang, Xiao-Li Xiao, Yun-Hong Sun, Sheng-An Zhang, Yan-Qi Dang, Kai Wang, Wen-Jun Zhou, Alfredo Caturano · 2025
Read Emodin Enhances Rosiglitazone’s Therapeutic Profile by Dual Modulation of SREBP1-Mediated Adipogenesis and PPARγ-Driven Thermogenesis by Meng Li, Yi-Rong Wang, Xue Wang, Xiao-Li Xiao, Yun-Hong Sun, Sheng-An Zhang, Yan-Qi Dang, Kai Wang, Wen-Jun Zhou, Alfredo Caturano (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12736021.txt.
Description
Background/Objectives: Rosiglitazone (RSG), a potent PPARγ agonist for type 2 diabetes mellitus (T2DM), induces adverse adipogenic effects that limit clinical use. We investigated whether emodin (1,3,8-trihydroxy-6-methylanthraquinone, EMO), a natural anthraquinone, mitigates RSG-induced complications while enhancing its insulin-sensitizing benefits in severe obesity.
Catalog record
| CREATOR | Meng Li, Yi-Rong Wang, Xue Wang, Xiao-Li Xiao, Yun-Hong Sun, Sheng-An Zhang, Yan-Qi Dang, Kai Wang, Wen-Jun Zhou, Alfredo Caturano |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |